Wordt geladen...
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of...
Bewaard in:
Gepubliceerd in: | Haematologica |
---|---|
Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , |
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
Ferrata Storti Foundation
2015
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4450629/ https://ncbi.nlm.nih.gov/pubmed/25769541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.120121 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|